Precision Medicine Treatment of Alzheimer’s Disease: Successful Randomized Controlled Trial

There is a critical need for effective therapeutics for Alzheimer’s disease. However, the majority of previous clinical trials have pre-determined a single treatment modality, such as a drug candidate or therapeutic procedure, which may be unrelated to the primary drivers of the neurodegenerative process. Therefore, a personalized, precision medicine approach, with increased data set size to include the potential contributors to cognitive decline for each patient, and treatment of the identified potential contributors, has emerged as a potentially more effective strategy. Recent proof-of-concept trials have provided clinical data that support this approach. Objective: To determine whether a precision medicine approach to Alzheimer’s disease at the mild cognitive impairment or early dementia stage is effective in a randomized controlled clinical trial.